Virtual Library
Start Your Search
M. Takahama
Author of
-
+
P2.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 210)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.02-033 - Actual Situation of Adjuvant Chemotherapy for NSCLC in Japan (ID 3214)
09:30 - 09:30 | Author(s): M. Takahama
- Abstract
Background:
Several Clinical Trials were revealed survival advantage of adjuvant chemotherapy (AC) for completely resected NSCLC (increased 5 year survival rate by 4% to 15%), and AC has been standard of care for completely resected stage II to IIIA NSCLC. Further more, on JLCSG study has been revealed survival advantage of adjuvant UFT treatment for Japanese stage I (size>2cm) patients. To investigate the practical situation of Adjuvant chemotherapy (AC) for completely resected NSCLC in our institution.
Methods:
We retrospectively reviewed completely resected NSCLC patients who were p-stage IA (Size > 2cm) to IIIA at our institution between 2005 and 2010. Enforcement status of AC, regimen and survival were analyzed.
Results:
Of the 648 had oncological indication of AC, but only 123 patients (19%) were received AC. Poor postoperative physical condition (25%), age (24%) and doctor’s decision (Tumor size nearly 2cm, AIS) (22%) were popular reasons for avoid to AC. Ten presents of patients refuse AC by their intention. Forty-nine percent of patients were received AC by platinum doublet regimen and 33% were UFT regimen. Treatment related death and severe adverse event were not observed in all AC treatment.
Conclusion:
AC is standard of care for completely resected stage II to IIIA NSCLC and safety performed in practical situation. But majority of patients could not receive it.
